Clinical Hematology International

Volume 1, Issue 3, September 2019, Pages 127 - 133

Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion

Authors
Brian D. Adkins1, *, Bipin N. Savani2, Garrett S. Booth1
1Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
2Department of Internal Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
*Corresponding author. Ph.: (615) 322-8871; Fax: (615) 343-4181. Email: badkins.pathology@outlook.com
Corresponding Author
Brian D. Adkins
Received 22 April 2019, Accepted 23 June 2019, Available Online 1 September 2019.
DOI
10.2991/chi.d.190630.001How to use a DOI?
Keywords
Sickle cell hepatopathy; Sickle cell disease; Apheresis; Red blood cell exchange; Exchange transfusion
Abstract

Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe hepatic crisis wherein sinusoidal red cell sickling leads to massive hepatocyte dysfunction and cholestatic laboratory findings. Acute SCIC is defined by abdominal pain with progressive hepatic injury associated with hyperbilirubinemia, renal failure, encephalopathy, and coagulopathy. Patients are generally managed with red blood cell exchange transfusion (RBCEx), when available, as this is a potentially fatal condition. Simple transfusion may be utilized in resource-poor environment or when patients refuse RBCEx. As less than 50 adult cases have been described in the literature, many of them with limited follow-up, randomized clinical trials comparing RBCEx with other treatments are currently unfeasible. Likewise, a chronic form exists, but is less well characterized, and is associated with persistent bilirubinemia and a variable course in terms of progressive hepatic disease. We undertake a brief review of the literature and discuss two cases of SCIC managed with RBCEx at our institution.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
1 - 3
Pages
127 - 133
Publication Date
2019/09/01
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.190630.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Brian D. Adkins
AU  - Bipin N. Savani
AU  - Garrett S. Booth
PY  - 2019
DA  - 2019/09/01
TI  - Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion
JO  - Clinical Hematology International
SP  - 127
EP  - 133
VL  - 1
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190630.001
DO  - 10.2991/chi.d.190630.001
ID  - Adkins2019
ER  -